

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:

June 25, 2002

David Saliwanchik

David R. Saliwanchik, Patent Attorney



8/25/02  
RECEIVED  
INFORMATION DISCLOSURE  
STATEMENT  
Examining Group 1243  
Patent Application  
Docket No. GJE-87  
Serial No. 10/081,599  
AUG 22 2002  
RECEIVED  
TECH CENTER 1600-12800

COPY OF PAPERS  
ORIGINALLY FILED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1743  
Applicant(s) : Cornelia Anna Mundt, Marianne Brueggemann  
Serial No. : 10/081,599  
Conf. No. : 9658  
Filed : February 20, 2002  
For : Immunoglobulin Control Region  
Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Attachments: Form PTO-1449 and references listed thereon

